Bevacizumab biosimilar (Eastern Biotech)

重组人源化抗VEGF单抗（东方百泰生物）

Report date: 2026/04/24 20:01:59

Base Information

Drug NameBevacizumab biosimilar (Eastern Biotech)

Drug Alias Name贝伐珠单抗生物仿制药（东方百泰生物）贝伐人源化单抗生物仿制药（东方百泰生物）贝伐赛珠单抗生物仿制药（东方百泰生物）贝伐单抗生物仿制药（东方百泰生物）JY-028

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionVascular endothelial growth factor A inhibitors

TargetsVascular endothelial growth factor A

Therapy Area/IndicationsWet age-related macular degenerationMacular DegenerationCarcinoma, Non-Small-Cell Lung +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsWet age-related macular degenerationMacular Degeneration

Inactive IndicationsCarcinoma, Non-Small-Cell LungColorectal Neoplasms

ATC CodeL01XC07